An Intervention Study for Subjects with Palmoplantar Pustulosis
Official Title
ANB019-003: A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis
Purpose
This study is being done to assess the effects of the experimental study drug (ANB019) in patients with PPP.
Could this study be right for you?
- Must have a clinical diagnosis of PPP for at least 6 months prior to screening
- Must have active pustules on palms and/or soles of feet
- BMI must be within the range of 18-36 kg/m2
- Subjects must be in otherwise good health
- Must not have any suspected autoimmune disorder or immune deficiency
- No major surgeries in the past 4 weeks
- No history of malignancy in the past 5 years
- No history of drug, alcohol, or other substance abuse